Vial

Vial is a verifiable Series B biotech company with ~$100M in funding and ~180 employees, indicating exceptional real-world traction and utility despite a low-quality submission. The project addresses a critical inefficiency in clinical trials (CRO market). However, the submission text contained unverifiable or false claims (e.g., 'most people have used my product', 'marketcap: null'), which significantly penalized the Response Quality and Traction Quality scores. The final score reflects the high verified value of the underlying business, adjusted downward for the poor submission integrity.